Cargando…

Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial

BACKGROUND: The beneficial effects of probiotic supplementation standard antibiotic therapies for Helicobacter pylori infection have been verified, but the ability of probiotic monotherapy to eradicate H. pylori remains unclear. AIM: To evaluate the accuracy and efficacy of specific Lactobacillus st...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shumin, Zhang, Meiyi, Yu, Leilei, Tian, Fengwei, Lu, Wenwei, Wang, Gang, Chen, Wei, Wang, Jialin, Zhai, Qixiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525740/
https://www.ncbi.nlm.nih.gov/pubmed/36193094
http://dx.doi.org/10.1155/2022/6432750
_version_ 1784800745665593344
author Wang, Shumin
Zhang, Meiyi
Yu, Leilei
Tian, Fengwei
Lu, Wenwei
Wang, Gang
Chen, Wei
Wang, Jialin
Zhai, Qixiao
author_facet Wang, Shumin
Zhang, Meiyi
Yu, Leilei
Tian, Fengwei
Lu, Wenwei
Wang, Gang
Chen, Wei
Wang, Jialin
Zhai, Qixiao
author_sort Wang, Shumin
collection PubMed
description BACKGROUND: The beneficial effects of probiotic supplementation standard antibiotic therapies for Helicobacter pylori infection have been verified, but the ability of probiotic monotherapy to eradicate H. pylori remains unclear. AIM: To evaluate the accuracy and efficacy of specific Lactobacillus strains against H. pylori infection. METHODS: Seventy-eight patients with H. pylori infection were treated with strain L. crispatus G14-5M (L. crispatus CCFM1118) or L. helveticus M2-09-R02-S146 (L. helveticus CCFM1121) or L. plantarum CCFM8610 at a dose of 2 g twice daily for one month. (14)C-urea breath test, the gastrointestinal symptom rating scale, serum pepsinogen concentrations, and serum cytokine concentrations of patients were measured at baseline and end-of-trial to analyze the effect of the Lactobacillus strains in eradicating H. pylori infection and reducing gastrointestinal discomfort in patients. In addition, the composition and abundance of the intestinal microbiota of patients were also measured at end-of-trial. RESULTS: The (14)C-urea breath test value of the three Lactobacillus treatment groups had decreased significantly, and the eradication rate of H. pylori had increased by the end of the trial. In particular, the eradication rate in the G14-5M treatment group was significantly higher than the placebo group (70.59% vs. 15.38%, P=0.0039), indicating that one-month administration of the G14-5M regimen was sufficient to eradicate H. pylori infection. The ingestion of Lactobacillus strains also ameliorated the gastrointestinal symptom rating scale scores, and the serum interleukin-8 concentrations of H. pylori-infected patients appeared to modulate the gut microbiota of patients. However, none of the Lactobacillus strains had a significant effect on general blood physiological characteristics, serum tumor necrosis factor α concentrations, or serum pepsinogen concentrations in the patients. CONCLUSION: Three Lactobacillus strains significantly alleviate the gastrointestinal discomfort and the gastric inflammatory response of H. pylori-infected patients. The activity of probiotics in eradicating H. pyloriinfection may be species/strain specific.
format Online
Article
Text
id pubmed-9525740
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-95257402022-10-02 Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial Wang, Shumin Zhang, Meiyi Yu, Leilei Tian, Fengwei Lu, Wenwei Wang, Gang Chen, Wei Wang, Jialin Zhai, Qixiao Can J Infect Dis Med Microbiol Research Article BACKGROUND: The beneficial effects of probiotic supplementation standard antibiotic therapies for Helicobacter pylori infection have been verified, but the ability of probiotic monotherapy to eradicate H. pylori remains unclear. AIM: To evaluate the accuracy and efficacy of specific Lactobacillus strains against H. pylori infection. METHODS: Seventy-eight patients with H. pylori infection were treated with strain L. crispatus G14-5M (L. crispatus CCFM1118) or L. helveticus M2-09-R02-S146 (L. helveticus CCFM1121) or L. plantarum CCFM8610 at a dose of 2 g twice daily for one month. (14)C-urea breath test, the gastrointestinal symptom rating scale, serum pepsinogen concentrations, and serum cytokine concentrations of patients were measured at baseline and end-of-trial to analyze the effect of the Lactobacillus strains in eradicating H. pylori infection and reducing gastrointestinal discomfort in patients. In addition, the composition and abundance of the intestinal microbiota of patients were also measured at end-of-trial. RESULTS: The (14)C-urea breath test value of the three Lactobacillus treatment groups had decreased significantly, and the eradication rate of H. pylori had increased by the end of the trial. In particular, the eradication rate in the G14-5M treatment group was significantly higher than the placebo group (70.59% vs. 15.38%, P=0.0039), indicating that one-month administration of the G14-5M regimen was sufficient to eradicate H. pylori infection. The ingestion of Lactobacillus strains also ameliorated the gastrointestinal symptom rating scale scores, and the serum interleukin-8 concentrations of H. pylori-infected patients appeared to modulate the gut microbiota of patients. However, none of the Lactobacillus strains had a significant effect on general blood physiological characteristics, serum tumor necrosis factor α concentrations, or serum pepsinogen concentrations in the patients. CONCLUSION: Three Lactobacillus strains significantly alleviate the gastrointestinal discomfort and the gastric inflammatory response of H. pylori-infected patients. The activity of probiotics in eradicating H. pyloriinfection may be species/strain specific. Hindawi 2022-09-23 /pmc/articles/PMC9525740/ /pubmed/36193094 http://dx.doi.org/10.1155/2022/6432750 Text en Copyright © 2022 Shumin Wang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Shumin
Zhang, Meiyi
Yu, Leilei
Tian, Fengwei
Lu, Wenwei
Wang, Gang
Chen, Wei
Wang, Jialin
Zhai, Qixiao
Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial
title Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial
title_full Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial
title_fullStr Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial
title_full_unstemmed Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial
title_short Evaluation of the Potential Protective Effects of Lactobacillus Strains against Helicobacter pylori Infection: A Randomized, Double-Blinded, Placebo-Controlled Trial
title_sort evaluation of the potential protective effects of lactobacillus strains against helicobacter pylori infection: a randomized, double-blinded, placebo-controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525740/
https://www.ncbi.nlm.nih.gov/pubmed/36193094
http://dx.doi.org/10.1155/2022/6432750
work_keys_str_mv AT wangshumin evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial
AT zhangmeiyi evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial
AT yuleilei evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial
AT tianfengwei evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial
AT luwenwei evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial
AT wanggang evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial
AT chenwei evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial
AT wangjialin evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial
AT zhaiqixiao evaluationofthepotentialprotectiveeffectsoflactobacillusstrainsagainsthelicobacterpyloriinfectionarandomizeddoubleblindedplacebocontrolledtrial